T細胞療法の市場規模、シェア、成長分析、モダリティ別、タイプ別、適応症別、エンドユーザー別、地域別 - 産業予測、2024～2031年

T細胞療法の世界市場規模は、2022年に28億3,000万米ドルと評価され、2023年の38億3,000万米ドルから2031年には430億米ドルに成長し、予測期間中（2024～2031年）のCAGRは35.3％で成長する見通しです。

がんは依然として世界の主要な死亡原因のひとつであり、2040年までに2,750万人の患者が増えると予測されています。既存の治療法では病気の進行を遅らせることはできますが、寛解を長期間持続させることは依然として課題です。これに対し、免疫療法、特にCAR-T療法、TCR療法、TIL療法などのT細胞療法は、副作用が少なく、腫瘍細胞を効果的に標的とし、排除する能力があることから、支持を集めています。この革新的なアプローチは、ヒトの免疫系の力を利用するもので、T細胞療法をがん治療における革新的なソリューションとして位置づけています。このような細胞療法の開発が加速し続ける中、この新興部門はバイオ医薬品業界で最も有利な市場のひとつとなる準備が整っています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 特許分析
• ケーススタディ

T細胞療法市場規模：治療タイプ別 & CAGR（2024～2031年）

• 市場概要
• CAR-T細胞療法
• 腫瘍浸潤リンパ球（TIL）療法
• T細胞受容体（TCR）に基づく治療

T細胞療法市場規模：モダリティ別 & CAGR（2024～2031年）

• 市場概要
• 調査利用
• 臨床使用

T細胞療法市場規模：適応症別 & CAGR（2024～2031年）

• 市場概要
• 造血悪性腫瘍
  • リンパ腫
  • 白血病
  • 多発性骨髄腫
• 固形腫瘍
  • 悪性黒色腫
  • 肺がん
  • 大腸がん
  • 乳がん
• 感染症
  • COVID-19
  • HIV
• 自己免疫疾患
  • 関節リウマチ
  • 多発性硬化症

T細胞療法市場規模：エンドユーザー別 & CAGR（2024～2031年）

• 市場概要
• 病院
• がん治療センター
• 調査機関

T細胞療法市場規模：地域別 & CAGR（2024～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021～2023年）

主要企業プロファイル

• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• Kite Pharma（USA）
• Juno Therapeutics（USA）
• Adaptimmune（UK）
• Bluebird Bio（USA）
• Cellectis（France）
• Bellicum Pharmaceuticals（USA）
• Sangamo Therapeutics（USA）
• Atara Biotherapeutics（USA）
• Autolus Therapeutics（UK）
• Immatics（Germany）
• Allogene Therapeutics（USA）
• Mustang Bio（USA）
• Celyad Oncology（Belgium）
• Genocea Biosciences（USA）
• Iovance Biotherapeutics（USA）

結論と推奨事項

Global T-Cell Therapy Market size was valued at USD 2.83 billion in 2022 and is poised to grow from USD 3.83 billion in 2023 to USD 43.0 billion by 2031, growing at a CAGR of 35.3% during the forecast period (2024-2031).

Cancer remains one of the leading causes of mortality worldwide, with projections indicating an addition of 27.5 million cases by 2040, imposing heavy financial, emotional, and physical strains on individuals and healthcare systems alike. While existing treatment options can slow disease progression, achieving long-lasting remission remains a challenge. In response, immunotherapies, particularly T-cell therapies such as CAR-T, TCR, and TIL therapies, are gaining traction for their ability to effectively target and eliminate tumor cells with fewer side effects. This innovative approach harnesses the human immune system's power, positioning T-cell therapy as a transformative solution in cancer treatment. As the development of these cell therapies continues to accelerate, this emerging sector is poised to become one of the most lucrative markets in the biopharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global T-Cell Therapy Market Segmental Analysis

Global T-Cell Therapy Market is segmented by therapy type, modality, indication, end-user and region. Based on therapy type, the market is segmented into CAR T-cell therapy, tumor-infiltrating lymphocytes (TIL) therapy and t cell receptor (TCR)-based therapy. Based on modality, the market is segmented into research use and clinical use. Based on indication, the market is segmented into hematologic malignancies, solid tumors, infectious diseases and autoimmune diseases. Based on end-user, the market is segmented into hospitals, cancer treatment centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is being significantly driven by the recent FDA approvals of Yescarta, Kymriah, and Tecartus, prompting numerous companies to pivot from developing traditional protein and small-molecule therapeutics to focus on adoptive therapies as their core business strategy. This shift has led to a remarkable increase in the T-cell therapy market, bolstered by strategic investments from both public and private sectors. The burgeoning gene therapy landscape plays a crucial role, as these advancements enhance the efficacy of CAR-T therapies. Additionally, the integration of T-cell approaches in cancer immunotherapy, combined with substantial funding dedicated to CAR T-cell research, is expected to propel the market, particularly with an expanding clinical trial environment for various hematologic cancers.

Restraints in the Global T-Cell Therapy Market

The T-cell therapy market faces significant constraints primarily due to the limited effectiveness of CAR-T therapies in treating solid tumors, compounded by safety concerns arising from the highly immunosuppressive tumor microenvironment. These challenges hinder market expansion, prompting industry stakeholders to explore innovative strategies to overcome these obstacles. Efforts are being made to enhance the applicability of CAR-T treatments in solid tumors, which may subsequently widen their therapeutic impact and improve patient outcomes. As the sector evolves, addressing these limitations will be crucial for tapping into the full potential of T-cell therapies in various oncological applications.

Market Trends of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is witnessing a notable trend towards the application of CAR T-cell therapies in the treatment of solid tumors, particularly in challenging cases such as diffuse midline glioma, a rare and aggressive pediatric cancer. Research highlights the potential of CAR T-cell treatment to significantly improve patient outcomes, with successful trials showing extended tumor eradication in animal models despite facing toxicity challenges. Intracerebroventricular (ICV) delivery methods are emerging as a safer, more efficient alternative to systemic administration, marking a pivotal shift in therapeutic strategies. This evolving landscape is expected to drive substantial growth in the T-Cell Therapy market, attracting investments and innovations tailored for solid tumor applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global T-Cell Therapy Market Size by Therapy Type & CAGR (2024-2031)

• Market Overview
• CAR T-Cell Therapy
• Tumor-Infiltrating Lymphocytes (TIL) Therapy
• T Cell Receptor (TCR)-Based Therapy

Global T-Cell Therapy Market Size by Modality & CAGR (2024-2031)

• Market Overview
• Research Use
• Clinical Use

Global T-Cell Therapy Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Multiple Myeloma
• Solid Tumors
  • Melanoma
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
• Infectious Diseases
  • COVID-19
  • HIV
• Autoimmune Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis

Global T-Cell Therapy Market Size by End-User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Research Institutes

Global T-Cell Therapy Market Size & CAGR (2024-2031)

• North America (Therapy Type, Modality, Indication, End-User)
  • USA
  • Canada
• Europe (Therapy Type, Modality, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellicum Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genocea Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations